Company Overview and News

2
Linn Energy Planning On Splitting Into 2 Companies Soon

2018-06-11 seekingalpha
Roan Resources will hold the Merge/SCOOP/STACK assets and has been growing rapidly with production now 60% higher than in September 2017.
LINEQ LNGG LINE

20
Revisiting MLP Distribution Growth

2018-06-06 seekingalpha
It's a perennial favorite, with investors and industry insiders requesting it over and over again. We wanted to provide a simple number that could be referenced and compared. Something like the GDP growth rate, which on its face is a quick look at the economy, but in reality, is a simplified summary of a nuanced subject.
LINEQ ETP.PRC LGCYP LGCYO BBPPQ LNGG VNRR BBEP WPZ ETP VNR LGCY VNRAP VNRBP VNRCP BBEPQ EEP PAA BBEPP LINE

2
25th Anniversary Of Financial Shenanigans With Howard Schilit

2018-06-01 valuewalk
Financial Reporting & Analysis Edition – “25th Anniversary of Financial Shenanigans with Howard Schilit” from a recent CFA NY conference
LINEQ LNGG LINE

2
Linn Energy's (LNGG) CEO Mark Ellis on Q1 2018 Results - Earnings Call Transcript

2018-05-03 seekingalpha
Linn Energy IncA (OTCQB:LNGG) Q1 2018 Results Earnings Conference Call May 3, 2018 11:00 AM ET
LINEQ LNGG LINE

2
LINN Energy Reports First-Quarter 2018 Results

2018-05-03 globenewswire
HOUSTON, May 03, 2018 (GLOBE NEWSWIRE) -- LINN Energy, Inc. (OTCQB:LNGG) (“LINN” or the “Company”) announces financial and operating results for the first quarter 2018 and highlights the following:
LINEQ LNGG LINE

9
CEO Awarded $60 Million to Lead Linn Energy Firm Past Bankruptcy - Bloomberg

2018-04-19 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
LINEQ LNGG XOM LINE

3
BRIEF-Linn Energy Provides A Strategic Update On Separation

2018-04-18 reuters
* LINN ENERGY PROVIDES A STRATEGIC UPDATE ON SEPARATION, ANNOUNCES NEW LEADERSHIP AND SCHEDULES FIRST QUARTER 2018 EARNINGS CONFERENCE CALL
LINEQ LNGG LINE

2
LINN Energy Provides a Strategic Update on Separation, Announces New Leadership and Schedules First Quarter 2018 Earnings Conference Call

2018-04-18 globenewswire
HOUSTON, April 18, 2018 (GLOBE NEWSWIRE) -- LINN Energy, Inc. (OTC:LNGG) (“LINN” or the “Company”) provides a strategic update on the previously announced separation, announces new leadership and schedules its first quarter 2018 earnings conference call.
LINEQ LNGG LINE

174
[Press] Natural Gas Liquids (NGLs) Industry Global Market Size, Growth, Trends, Share and 2023 Forecasts Report

2018-04-10 oilvoice
Natural Gas Liquids (NGLs) Industry report offers a comprehensive insight into the development policies and plans in addition to manufacturing processes and cost structures. On the basis of product, this report displays the Cost Structure, Sales Revenue, Sales Volume, Gross Margin, market share and growth rate.
XOM LNGG CHKVP DVN BP RRL RDSB RDSA CHKDH CHKVZ SWTF CHKDG SU COP CHKDJ CHKDP SFY RYDAF CHK.PRD SU LINEQ CKRGZ RDS.B RDS.A SM SBOW RRS BP.A BP.B RGRLF CHKWZ RRC BP RGRYY CNQ CHK.WI CHK RYDBF STOHF BPAQF LINE STO

4
Valuing Mid-Con Energy Partners Based On PV-10 And EBITDA

2018-04-09 seekingalpha
Based on the PV-10 of its reserves and other mature asset sales, Mid-Con's value is estimated at $1.88 per common unit.
LINEQ LNGG LINE MCEP

7
Breitburn Energy Partners: Bankruptcy Proceedings Are Nearing The End

2018-03-21 seekingalpha
Second-lien bondholders will receive a strong recovery via ownership of Breitburn's legacy assets, while unsecured bondholders will receive a modest recovery.
LINEQ BBPPQ LNGG BBEP BBEPQ BBEPP LINE

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

20h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...